Hair Growth Treatment
Dermaliq, a clinical-stage dermatology and aesthetics company, has announced topline results from their Phase 1b/2a trial evaluating DLQ01, a topical prostaglandin F2 alpha analog, for the treatment of androgenic alopecia in men. What is DLQ01? DLQ01 is a topical treatment indicated for male and female pattern baldness that utilizes Dermaliq’s proprietary hyliQ® technology. This formulation…
Correction (07/05/2024): Topadur Pharma has been in contact (read the comments below) and let us know that TOP-M119 does not contain sildenafil and nitroglycerin. We have corrected the reference to this in the article below. The information originated from a website called Il Messaggero, quote “The most curious thing is that the currently candidate drug,…
Equillium, a clinical-stage biotechnology company, has reported its findings from a phase 2 study of EQ101, a new treatment for patients with moderate to severe alopecia areata (AA). What is EQ101? EQ101 is a first-in-class, selective, tri-specific inhibitor that targets IL-2, IL-9, and IL-15 proteins involved in the immune response. These proteins have been implicated…
Lumenis Be. Ltd, an energy-based medical device company specializing in aesthetic and eye care solutions, has introduced FoLix™, a fractional laser system for treating hair loss. Recently cleared by the FDA, FoLix is the first fractional laser to be cleared for hair loss treatment for both women and men in the United States. What is…
Soterios Pharma, a biopharmaceutical company based in the UK, has announced promising topline results from their Phase 2 study of STS-01, a topical treatment for mild-to-moderate alopecia areata (AA). What is STS-01? STS-01 is a topical treatment for alopecia areata. It is a cytokine-targeting agent that modulates the inflammatory response and T-cell proliferation by disrupting…
JW Pharmaceutical has presented positive preclinical data on JW0061, a novel Wnt-targeted hair loss treatment, at the U.S. Society of Investigative Dermatology meeting. What are Wnt-Targeted Hair Loss Treatments? Wnt-targeted hair loss treatments aim to modulate the Wnt/ß-catenin signaling pathway, which plays an important role in hair follicle development, hair growth cycle regulation, and hair…
Follicle Thought is pleased to present a recent interview we conducted with Geoff Hamilton, the CEO of Stemson Therapeutics. Stemson Therapeutics is a biotech company founded in 2018 that aims to revolutionize hair regrowth through stem cell technology. So, let’s get into the interview. FT: Hi Geoff, Thank you for coming back to Follicle Thought…
This week, there is interesting news for those with alopecia areata. Nektar Therapeutics has announced that it will launch a Phase 2b trial for its drug rezpegaldesleukin (REZPEG), which will be assessed in individuals suffering from severe to very severe alopecia areata (AA). Nektar Therapeutics is a biotech firm with several indications in the pipeline…
Pelage Pharma Presents Data From its Phase 1 Clinical Study: Update (03/09/2024) On March 9th, Pelage Pharma unveiled data at the AAD 2024 Annual Meeting, showcasing PP405. Through translational and Phase 1 clinical studies, PP405 demonstrated its ability to reactivate dormant hair follicle stem cells, triggering hair regrowth. Pelage Pharma has provided an overview of…
Earlier this month, Stemson Therapeutics announced its hair follicle regeneration research advancement. What is Stemson Therapeutics Working On? The company is focused on developing a cell therapy solution for hair loss. They use autologous (meaning from the self) induced pluripotent stem cells (iPSCs) to engineer follicular units to form new hair follicles. These will be…